Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

There is still hope for Takeda's antisepsis drug, TAK-242

February 24, 2009

Analysis of:Discontinuation of Development of TAK-242 for Severe Sepsis | www.pipelinereview.com

TAK-242 is a novel, selective inhibitor of Toll-like receptor 4 (TLR4) signaling. TLR4 is the receptor for the "endotoxin" LPS, which is released from pathogens and causes sepsis and multiple organ failure. In contrast to many previous failed antisepsis drugs, TAK-242 appears to be a common pathway inhibitor, and as such has a better chance of success if the right patient population is treated. The Phase III trial has been stopped after an interim analysis by the DSMB found not sufficient cytokine lowering by the drug.In my opinion, the patients, who would benefit most are the ones with "moderate" or early stages of sepsis ( in advanced stages, no drug works!) and should be screened for ther specific microbial infection which would respond to the drug best.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS